Circulating MicroRNAs as novel biomarkers for platelet activation

Circulation Research

Volumn 112, Issue 4, 2013, Pages 595-600

  Willeit, Peter ^a,b   Zampetaki, Anna ^c   Dudek, Katarzyna ^c   Kaudewitz, Dorothee ^c   King, Alice ^d   Kirkby, Nicholas S ^e,f   Crosby Nwaobi, Roxanne ^g   Prokopi, Marianna ^c   Drozdov, Ignat ^c   Langley, Sarah R ^c   Sivaprasad, Sobha ^g   Markus, Hugh S ^d   Mitchell, Jane A ^e   Warner, Timothy D ^f   Kiechl, Stefan ^a   Mayr, Manuel ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antiplatelet therapy; biomarkers; microRNAs; platelet inhibitors; platelets

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; MICRORNA; PRASUGREL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PLASMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; THROMBOCYTE ACTIVATION; VALIDATION STUDY; VOLUNTEER;

ADULT; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD SPECIMEN COLLECTION; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; PIPERAZINES; PLASMA; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET-RICH PLASMA; REAL-TIME POLYMERASE CHAIN REACTION; SERUM; THIOPHENES; YOUNG ADULT;

EID: 84874230935     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.300539     Document Type: Article

References (15)

1. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
2. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508-522.
3. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107: 810-817.
4. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60:290-299.
5. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res. 2012;93:555-562.
6. Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, Boulanger CM, Westwood N, Urbich C, Willeit J, Steiner M, Breuss J, Xu Q, Kiechl S, Mayr M. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood. 2009;114: 723-732.
7. Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, Mitchell JA, Warner TD. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost. 2011;9:2050-2056.
8. King A, Bath PM, Markus HS. Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke. 2011;42:650-655.
9. Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost. 2012;108:592-598.
10. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-684.
11. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011;124:1936-1944.
12. Engelhardt S. Small RNA biomarkers come of age. J Am Coll Cardiol. 2012;60:300-303.
13. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res. 2011;128:352-357.
14. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
15. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators. Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012;59:1928-1937.